Tygacil safety alert – FDA

Health care professionals should reserve Tygacil for use in situations when alternative treatments are not suitable.

This analysis showed a higher risk of death among patients receiving Tygacil compared to other antibacterial drugs: 2.5% (66/2640) vs. 1.8% (48/2628), respectively. The adjusted risk difference for death was 0.6% with corresponding 95% confidence interval (0.0%, 1.2%). In general, the deaths resulted from worsening infections, complications of infection, or other underlying medical conditions.


Tygacil (tigecycline): Drug Safety Communication – Increased Risk of Death, Sept 27th 2013